Status: Recruiting
Teclistamab-Daratumumab in AL Amyloidosis
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Participants needed: 25
Trial details
Phase: Phase 2Age: 18-100Biological sex: AllType: InterventionalSponsor: Rajshekhar Chakraborty, MDUpdated: Jul 13, 2026Locations: 3
Eligibility criteria
Age >18 years and able to sign Informed Consent Form (ICF). If the individual be... [+15]
Prior therapy for AL amyloidosis or multiple myeloma with the exception of 160 m... [+10]